본문 바로가기

Secukinumab 치료 실패 후 ixekizumab으로 성공적으로 치료된 판상 건선 1예

A Case of Plaque Psoriasis Successfully Treated with Ixekizumab Following Secukinumab Failure

문서 유형
연구출판물 · 학술지 논문
등재
KCI
저널
대한건선학회지18(2) · pp.54 · 2021
피인용
KCI 1
ISSN
2384-1176

저자

  1. 윤지상제1저자부산대학교병원 피부과학교실
  2. 김성준아름다운피부과의원
  3. 배경남부산대학교병원
  4. 손진화부산대학교병원
  5. 신기혁부산대학교병원
  6. 김훈수부산대학교병원 피부과학교실
  7. 고현창부산대학교병원 피부과학교실
  8. 김문범부산대학교병원 피부과학교실
  9. 김병수교신저자부산대학교

초록

If there is no improvement of the lesion despite the use of a biological agent, a change to another agent may be considered, and successful ‘intra-class switching’ has been reported. The reason for the effect of changes within the same class is explained as different depending on the molecular structure and pharmacokinetic characteristics of the drug. Pharmacokinetics may show differences in molecular affinity and half-life. Herein, we report a case of successful treatment with ixekizumab, the same IL-17A inhibitor class drug, after secukinumab treatment failure. The patient was diagnosed with psoriasis on histological examination, and treatment with secukinumab was started in November 2017. However, from the 5th month onwards, there was an insufficient response, and psoriasis worsened, and the treatment was judged as a failure and then stopped. Ixekizumab was started in December 2019, and almost all lesions have improved and remained stable thereafter.

키워드

IxekizumabPsoriasisSecukinumab

식별자

KCI
ART002795488